Browse the evidence

LIGHT 2 is a seamless, adaptive phase 2b/3 trial evaluating the efficacy and safety of efsubaglutide alfa for chronic weight management in adults with overweight or obesity.

This trial aims to provide evidence on the effectiveness of efsubaglutide alfa for weight management.

The primary efficacy endpoint is percentage change in body weight.

The trial will measure how effective efsubaglutide alfa is at reducing body weight.

The guidelines provide context-specific recommendations tailored to individual patient needs.

Healthcare providers should customize obesity management strategies for individual patients.

The guidelines include recommendations for situations with limited resources.

Providers in resource-limited settings can utilize these guidelines to optimize care.

Among a subgroup of members on tirzepatide, semaglutide, or with exposure to both, 86.5% of members had at least a 5% reduction in body weight from baseline at 6 months.

These medications are effective for significant weight loss in adherent patients.

Cardiac rehabilitation (CR) significantly improves functional capacity, cardiovascular risk factors, and quality of life in patients with obesity.

Practitioners should implement CR programs to enhance health outcomes in obese patients with cardiovascular issues.

Integrating nutrition and incretin therapies may improve weight-loss durability and adherence.

Practitioners should consider integrated approaches for better long-term weight management.

Approximately two-thirds of patients showed stable weight or continued weight loss during the 6 months following their last semaglutide or tirzepatide prescription.

Practitioners can expect that a significant portion of patients may maintain or lose weight after discontinuing GLP-1RA.

Tirzepatide treatment was associated with a mean percentage weight change of -13.3% for 5 mg and -21.3% for 15 mg compared to placebo from randomization to 72 weeks among participants using weight-inducing medications in SURMOUNT-1.

Practitioners can consider tirzepatide as an effective option for weight loss in patients requiring weight-inducing medications.

In SURMOUNT-3, the mean percentage weight change for the maximum tolerated dose of tirzepatide was -26.1% from randomization to 72 weeks among participants using weight-inducing medications.

Practitioners can consider higher doses of tirzepatide for significant weight loss in patients on weight-inducing medications.

Tirzepatide treatment was associated with weight loss comparable to primary study results among participants taking weight-inducing medications.

Practitioners can confidently recommend tirzepatide for weight loss in patients on weight-inducing medications.

Eine Therapie mit GLP-1-RA kann erfolgreich sein, wenn sie mit nicht-medikamentösen Maßnahmen kombiniert wird.

Die Kombination von GLP-1-RA mit Lebensstiländerungen ist entscheidend für den Therapieerfolg.

Progress logging was associated with greater weight loss over time.

Encouraging users to log their progress can lead to better weight loss results.

Retatrutide yields a 24.2% reduction in total body weight at 48 weeks with 63% of participants achieving a total body weight loss of ≥20%.

Retatrutide may be an effective option for significant weight loss in patients.

Tirzepatide treatment resulted in a mean weight loss of 9.94 ± 4.8 kg and a percentage weight loss of 9.7 ± 4.8 % after 4 months.

Tirzepatide can be an effective option for weight management in patients with obesity.

Significant reductions were observed in body weight, BMI, waist circumference, absolute fat mass, body fat percentage, and visceral fat index.

Tirzepatide effectively reduces various measures of body fat in patients with obesity.

Protein supplementation has no negative effects on kidney performance in healthy adults who perform resistance training.

Practitioners can consider protein supplementation safe for kidney health in healthy adults engaged in resistance training.

Protein and amino acid supplements are widely used by military personnel to increase muscle mass, enhance recovery, and support physical performance.

Practitioners should recognize the common use of protein supplements among military personnel for performance and recovery.

The DG3D study evaluates the effectiveness of culturally adapted USDG dietary patterns in improving diet quality and reducing risk factors associated with T2DM among AA adults.

Practitioners can utilize culturally tailored dietary interventions to improve health outcomes in high-risk populations.

Primary outcomes of the DG3D study include changes in diet quality, body weight, and hemoglobin A1c (HbA1c).

Monitoring these outcomes can help assess the impact of dietary interventions on health.

In diabetic patients with poor control, a nutritional educational intervention that promotes the Mediterranean diet improves adherence to said diet, increasing the consumption of healthy foods and decreasing harmful ones.

Practitioners should consider implementing nutritional educational interventions to enhance adherence to the Mediterranean diet in patients with type 2 diabetes.

Weight loss through a healthy lifestyle can reduce morbidity and mortality associated with diabesity.

Encouraging weight loss through lifestyle changes is essential in managing diabesity.

The HoDiRECT Nepal project demonstrated the feasibility of a low-calorie traditional Nepali diet for diabetes remission.

Practitioners can consider low-calorie traditional diets as a viable option for diabetes remission.

Participants' motivation to enroll in the program was driven by their desire to stop taking diabetes medications, achieve better diabetes control, and lose weight.

Understanding participant motivations can help tailor interventions for diabetes management.